Pfizer is faced with an investment resistance due to the uncertainty of tariffs in the United States
Albert Bourla, CEO of Pfizer, told investors that uncertainty about imported drug tariffs planned by President Donald Trump keeps investing the company more in US factories and research laboratories.
During Tuesday's first quarter profit speech, Bourla was asked what confirmations from the company's trade negotiators need Increase domestic investments. Cnbc reportedher answer crazye cleartand fees forward drugs come The United States are the main A roadblock.
The Trump Administration has claimed that such Tariffs would promote more production on American surface.
“If I know there are no tariffs, there may be a tremendous amount of investment in this country, both in scientific and development and production,” Bourla said. He added that Pfizer is search Before dedicating to new projects “Castle”.
He explained that companies tend to guard their spending carefully. “During periods of uncertainty, everyone checks their cost As we do, and then be Very frugal with them Investment, As we do, so we are ready for the futureTo. So I want to see it. ”
On the tax front, Bourla pointed out that the introduction of the OECD's worldwide minimal tax last year has not necessarily made US investments more attractive. He emphasized that the lack of additional stimuli or clear policy around Trump's tariffs continues to prevent further investment in US production and research.
“Now [Trump] I'm sure – and know because I talked to him that he would like to see uniform decrease in the current tax mode Especially in the case of on -site goods, ”Bourla said. He suggested that additional cutting of domestic production may be a powerful Draw companies to build plants and laboratories in America.
Pfizer holding firmly The financial forecast of this whole year, despite their unity of trade.
Unlike many companies facing trade policy shifts, Pfizer left their Forecast of the whole year untouched Tuesday.
In a profit exhaust, the company stated that its instructions “does not currently cover the potential impact on future tariffs and trade policy changes that we are currently unable to predict.”
But in a profit speech, Dave Denton, CFO of Pfizer:
“This includes our instructions that we didn't really talk about whether there are some tariffs today,” he continued. “We are considering it within our guidance range and we will continue to go again until the end of our coaching range, even at the cost of this year.”
Denton said these existing obligations are about $ 150 million.
The company confirmed the goal of sales of its entire year 2025 for $ 61-64 billion, predicting that its cooled products will operate at about the same level in 2024.
Bourla said Pfizer has founded a dedicated team to consider different tariff scenarios and highlight plans to reduce any decline in both soon and longer transport. This group is focused on managing current stock levels in key areas, leaning on Pfizer US factories and other steps to keep the company smooth.
“If we will be affected by further tariffs in the future, we will evaluate the impact of established policies and provide information at a suitable time,” Bourla said, stating that the company will continue to monitor Washington's commercials before any major new obligations.
Cryptopolitan Academy: Do you want to raise your money in 2025? Here's how to do this in our upcoming web class. Save your place
